AMARIN CORP PLC\UK Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation
AMARIN CORP PLC\UK (AMRN) reported Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation of $94.00 thousand for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-05.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation · last filed 2017-03-01
- AMARIN CORP PLC\UK adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2016-03-31 was $94.00K.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, income tax deficiency from share-based compensation for fiscal 2014 was $2.30M, a 536.84% increase from fiscal 2013.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, income tax deficiency from share-based compensation for fiscal 2013 was $361.00K.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 12 month |
|---|---|---|
| 2016-03-31 | $94.00K 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $2.30M 10-K · filed 2017-03-01 | |
| 2013-12-31 | $361.00K 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |